Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $48.20

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have earned an average rating of "Buy" from the seven research firms that are presently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $48.20.

OTLK has been the subject of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a report on Thursday, August 15th. Ascendiant Capital Markets lowered their price objective on shares of Outlook Therapeutics from $35.00 to $33.00 and set a "buy" rating on the stock in a research report on Tuesday, September 3rd. Finally, Chardan Capital restated a "buy" rating and set a $53.00 price target on shares of Outlook Therapeutics in a research report on Friday, August 16th.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of OTLK. AQR Capital Management LLC purchased a new position in Outlook Therapeutics in the second quarter worth about $75,000. Squarepoint Ops LLC purchased a new stake in Outlook Therapeutics in the 2nd quarter worth approximately $232,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Outlook Therapeutics during the 2nd quarter valued at $303,000. LVW Advisors LLC purchased a new position in shares of Outlook Therapeutics in the second quarter valued at about $352,000. Finally, Rosalind Advisors Inc. lifted its holdings in Outlook Therapeutics by 44.3% in the 2nd quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company's stock worth $3,321,000 after purchasing an additional 138,225 shares in the last quarter. 11.20% of the stock is owned by hedge funds and other institutional investors.

Outlook Therapeutics Trading Down 2.7 %

Shares of OTLK traded down $0.22 on Tuesday, reaching $7.79. The company's stock had a trading volume of 255,839 shares, compared to its average volume of 360,295. Outlook Therapeutics has a twelve month low of $4.09 and a twelve month high of $18.00. The firm has a fifty day moving average of $7.69 and a 200-day moving average of $7.95. The stock has a market capitalization of $182.33 million, a PE ratio of -0.71 and a beta of 0.64.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.83) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.23. As a group, equities analysts anticipate that Outlook Therapeutics will post -3.65 EPS for the current fiscal year.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.